Company news

Alpha Cognition Inc. news in 2025

Alpha Cognition Inc.'s news releases, calls and decks from 2025, newest first.

View company

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

December 1, 2025

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

November 13, 2025

Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

October 30, 2025

Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference

October 15, 2025

Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

October 14, 2025

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

October 6, 2025

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

September 30, 2025

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

September 30, 2025

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

August 28, 2025

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

August 14, 2025

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

August 4, 2025

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease

July 29, 2025

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference

July 8, 2025

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

July 1, 2025

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

May 15, 2025

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

May 1, 2025

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

April 30, 2025

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference

April 28, 2025

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

April 10, 2025

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

March 31, 2025

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

March 19, 2025

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

March 18, 2025

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

February 11, 2025

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

January 13, 2025

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

January 7, 2025

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

January 5, 2025

Calls in 2025

Decks in 2025